Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies
Status:
Withdrawn
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of ETC-1907206 in combination with dasatinib in certain types of
blood cancers. The first phase of the study (1A) is designed to find the highest tolerated
dose of ETC-1907206, while the second phase (1B) will assess the safety and tolerability of
the recommended dose of ETC-1907206. ETC-1907206 has been designed to block the activity of
an enzyme of the body known as Mnk kinase, which is thought to be involved in the development
of a variety of cancers.
Phase:
Phase 1
Details
Lead Sponsor:
D3 (Drug Discovery and Development), A*STAR Research Entities EDDC (Experimental Drug Development Centre), A*STAR Research Entities